Where does Pulmocide Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pulmocide Limited ranks #14,220 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pulmocide Limited hold?

Pulmocide Limited holds 21 US utility patents granted between 2017 and 2025, spanning 5 technology areas.

What is Pulmocide Limited's Innovation Score?

Pulmocide Limited has an Innovation Score of 27.5 out of 100 (24th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Pulmocide Limited focus on?

Pulmocide Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 21 patents, ranking #933 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Pulmocide Limited's patent grant rate increasing or decreasing?

Pulmocide Limited's recent grant velocity is -57% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Pulmocide Limited's patents?

Pulmocide Limited's patents average 14.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pulmocide Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Pulmocide Limited

USPTO PatentsView assignee record - 21 granted patents across 5 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pulmocide ranks #14,220 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 5 technology areas.

#14,220
of 49,997 US assignees by volume: 24th percentile
by Innovation Score (27.5/100): 14.0
avg claims per patent: -57%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14220 · Foreign Corporation #14,220 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #14,220/49,997
PHOTO-FINISH Packaging of America
CPC-NARROW A61P · 5 areas
INNOV-THIN 27.5/100
CLAIMS-RICH 14.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -57% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Packaging Corporation of America (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pulmocide’s 27.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (39%) Velocity 0.5 pts (2%) Breadth 7.9 pts (29%) Claim depth 8.4 pts (31%)

Qualcomm Incorporated · highest

85
2724889 Ontario · near

28
LNJ Group · near

28
Pulmocide · this assignee

28
Taisei Lamick · near

28
Worldwise · near

27
3D Lighting… · lowest

7

What this shows Pulmocide's Innovation Score is 27.5/100 (24th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pulmocide?

Each dot is one of Pulmocide’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pulmocide’s own 14.0 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Pulmocide vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pulmocide's grants concentrate

Pulmocide Limited is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (8 grants) versus a trough of 1 in 2017. By volume, Pulmocide sits between Perspecta Labs Inc. and Physiowave, Inc..

Pulmocide's three-year grant acceleration

Pulmocide Limited shows 1 grants in 2022–2024 against only 13 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Perspecta Labs

21
Petromac IP

21
Powercell Sweden…

21
Prime Polymer

21
Packaging of Amer…

21
Petrowell

21
Phibro Animal Hea…

21
Physiowave

21
Pulmocide ◀

21

What this shows Pulmocide holds 21 patents at rank #14,202, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pulmocide

By rank, the assignees closest to #14,202 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Pulmocide's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Pulmocide, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Pulmocide ranks #933 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (28 here).

2724889 Ontario Inc. 28 LNJ Group, LLC 28 Taisei Lamick Co., Ltd. 28 Worldwise, Inc. 27

Pulmocide's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 24th percentile higher than 24% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Pulmocide Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	4.8%
2018	5	23.8%
2019	8	38.1%
2020	4	19.0%
2021	1	4.8%
2023	1	4.8%
2025partial year	1	4.8%

Which technologies does Pulmocide Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 21

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 21

C07D - Heterocyclic Compounds 21

G06F - Electric Digital Data Processing 10

G11C - Static Stores 10

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pulmocide Limited's patent record in context - here's where to go next.

Pulmocide Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #14,220 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pulmocide Limited against Perspecta Labs Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.